Procalcitonin (PCT) is useful for differentiating between viral and bacterial infections and for
reducing the unnecessary use of antibiotics. As the rise of antimicrobial resistance reaches …

To the Editor—Prior to the coronavirus disease 2019 (COVID-19) pandemic, serum
procalcitonin (PCT)-based antimicrobial stewardship (AMS) algorithms have been shown to …

Antibacterial prescribing in patients presenting with COVID-19 remains discordant to rates of
bacterial co-infection. Implementing diagnostic tests to exclude bacterial infection may aid …

Accumulating evidence supports procalcitonin (PCT) as an accurate surrogate biomarker for
likelihood and severity of bacterial infections. In community-acquired pneumonia and other …

Objective: To evaluate the role of procalcitonin (PCT) results in antibiotic decisions for
COVID-19 patients at hospital presentation. Design, setting, and participants: Multicenter …

The development of secondary bacterial infections in COVID-19 patients has been
associated with increased mortality and worse clinical outcomes. Consequently, many …

Introduction Procalcitonin (PCT) is an emerging prognostic marker in coronavirus disease
2019 (COVID-19). Whether PCT can detect secondary bacterial infections or reflect target …

Background Procalcitonin is a biomarker that may be able to identify patients with COVID-19
pneumonia who do not require antimicrobials for bacterial respiratory tract co-infections …

It can be a diagnostic challenge to identify patients with coronavirus disease 2019 in whom
antibiotics can be safely withheld. This study evaluated the effectiveness of a guideline …

Background It can be a diagnostic challenge to identify COVID-19 patients without bacterial
co-infection in whom antibiotics can be safely stopped. We sought to evaluate the validity of …